Fast-track to UK market: Mastering the MHRA's recognition procedure
This audiogram is part of The Regulatory Navigator series, where we explore the evolving regulatory landscape with actionable insight from Parexel's experts, sharing their experience to maximize success for clinical development and patient access.
The MHRA's International Recognition Procedure (IRP) is transforming medicines licensing and creating unprecedented opportunities to accelerate your product's journey to market. This game-changing pathway could dramatically reshape your global submission strategy.
Get the insider advantage. Our team of former MHRA regulators reveals exclusive insights to help you:
- Fast-track your authorization process
- Strategically optimize your global submission sequence
- Gain competitive edge in market entry timing
Related Insights
Blog
EMA’s evolving stance on external controls: Key takeaways and preparation strategies for sponsors
Dec 10, 2025
Blog
The EU-CTR transition: Four key ways to prepare now
Jan 12, 2024
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Related Insights
Blog
EMA’s evolving stance on external controls: Key takeaways and preparation strategies for sponsors
Dec 10, 2025
Blog
The EU-CTR transition: Four key ways to prepare now
Jan 12, 2024
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023